Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGF-β1 signaling
Metrics: PDF 1156 views | HTML 1745 views | ?
Yun Luan1, Luan Zhang2, Sun Chao1, Xiaoli Liu3, Kaili Li1, Yibiao Wang2, Zhaohua Zhang2
1Central Research Laboratory, The Second Hospital of Shandong University, Jinan, China
2Department of Pediatrics, The Second Hospital of Shandong University, Jinan, China
3Department of Hematology, The Second Hospital of Shandong University, Jinan, China
Yibiao Wang, e-mail: [email protected]
Zhaohua Zhang, e-mail: [email protected]
Keywords: BPD, MSCs, EPO, TGF-β1, ETM
Received: December 09, 2015 Accepted: April 11, 2016 Published: May 12, 2016
The aim of the present study is to investigate the protection effects of bone marrow mesenchymal stem cells (MSCs) in combination with EPO against hyperoxia-induced bronchopulmonary dysplasia (BPD) injury in neonatal mice. BPD model was prepared by continuous high oxygen exposure, 1×106 bone marrow MSCs and 5000U/kg recombinant human erythropoietin (EPO) were injected respectively. Results showed that administration of MSCs, EPO especially MSCs+EPO significant attenuated hyperoxia-induced lung damage with a decrease of fibrosis, radical alveolar counts and inhibition of the occurrence of epithelial-mesenchymal transition (EMT). Furthermore, MSCs+EPO co-treatment more significantly suppressed the levels of transforming growth factor-β1(TGF-β1) than MSCs or EPO alone. Collectively, these results suggested that MSCs, EPO in particular MSCs+EPO co-treatment could promote lung repair in hyperoxia-induced alveoli dysplasia injury via inhibition of TGF-β1 signaling pathway to further suppress EMT process and may be a promising therapeutic strategy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.